AstraZeneca's Tagrisso shows 47% death risk reduction at eight years
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
September 13, 2026 9:47 PM EDTLongest survival data ever reported in a global Phase III trial in this setting
New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages
WILMINGTON, Del.--(BUSINESS WIRE)-- Updated exploratory results from the ADAURA Phase III trial showed AstraZenecas TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer... More
